B, D., A, P., MU, M., AM, C., E, F., Z, M., . . . F, A. (2019). Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leukemia & lymphoma, 60(10), 2558. https://doi.org/10.1080/10428194.2019.1585836
Chicago Style (17th ed.) CitationB, Dhakal, et al. "Versican Proteolysis Predicts Immune Effector Infiltration and Post-transplant Survival in Myeloma." Leukemia & Lymphoma 60, no. 10 (2019): 2558. https://doi.org/10.1080/10428194.2019.1585836.
MLA (9th ed.) CitationB, Dhakal, et al. "Versican Proteolysis Predicts Immune Effector Infiltration and Post-transplant Survival in Myeloma." Leukemia & Lymphoma, vol. 60, no. 10, 2019, p. 2558, https://doi.org/10.1080/10428194.2019.1585836.
Warning: These citations may not always be 100% accurate.
